Monitor: molecules and profiles.

abstract：:The Science for Life Laboratory Drug Discovery and Development (SciLifeLab DDD) platform reaches out to Swedish academia with an industry-standard infrastructure for academic drug discovery, supported by earmarked funds from the Swedish government. In this review, we describe the build-up and operation of the platform...

journal_title：Drug discovery today

authors： Arvidsson PI,Sandberg K,Forsberg-Nilsson K

更新日期：2016-10-01 00:00:00

abstract：:Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

journal_title：Drug discovery today

authors： Westwell AD

更新日期：2001-11-15 00:00:00

abstract：:Regenerative approaches are promising avenues to effectively cure diseases rather than merely treating symptoms, but are associated with concerns around proliferation in other organs. Given that targeted delivery holds the promise of delivering a drug precisely to its desired site of action, usually with the prospect ...

journal_title：Drug discovery today

authors： Valeur E,Knerr L,Ölwegård-Halvarsson M,Lemurell M

更新日期：2017-06-01 00:00:00

abstract：:Glycosaminoglycans (GAGs) are charged polysaccharides ubiquitously present at the cell surface and in the extracellular matrix. GAGs are crucial for cellular homeostasis, and their metabolism is altered during pathological processes. However, little consideration has been given to the regulation of the GAG milieu thro...

journal_title：Drug discovery today

authors： Ghiselli G,Maccarana M

更新日期：2016-07-01 00:00:00

abstract：:Cancer and arthritis present an enormous challenge to society. They share pathogenic pathways that involve extracellular matrix degradation, tissue invasion, and inflammation. Most cancer and arthritis treatments affect normal cell function to cause significant adverse effects in patients. Specific pathways that promo...

journal_title：Drug discovery today

authors： Krishnan H,Miller WT,Blanco FJ,Goldberg GS

更新日期：2019-01-01 00:00:00

abstract：:3D bioprinting has emerged as the intersection between chemistry, biology and technology. Through its integration of cells, biocompatible materials and robotic-controlled dispensing systems, the process enables the production of structures that are biomimetic and functional, thus revolutionizing the concept of tissue ...

journal_title：Drug discovery today

authors： Parak A,Pradeep P,du Toit LC,Kumar P,Choonara YE,Pillay V

更新日期：2019-01-01 00:00:00

abstract：:Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be bene...

journal_title：Drug discovery today

authors： Hofmann F,García-Echeverría C

更新日期：2005-08-01 00:00:00

abstract：:2018 was a remarkable year, both in terms of the number of new molecular entities (NMEs) approved and the organizations developing them. In total, 59 NMEs received a nod from the US Food and Drug Administration (FDA), most of which were approved using a priority or breakthrough designation. Orphan drugs accounted for ...

journal_title：Drug discovery today

authors： Kinch MS,Griesenauer RH

更新日期：2019-09-01 00:00:00

abstract：:The use of computational filters for excluding supposedly nonspecific and promiscuous compounds from chemical libraries is a controversial issue, because many drugs used in clinics today would never reach the market if these filters were applied. In part, this conflict could be caused by the paradigm: one-drug-one-tar...

journal_title：Drug discovery today

authors： Senger MR,Fraga CA,Dantas RF,Silva FP Jr

更新日期：2016-06-01 00:00:00

abstract：:Model-based drug discovery (MBDDx) aims to build and continuously improve the quantitative understanding of the relation between drug exposure (target engagement) efficacy and safety, to support target validation; to define compound property criteria for lead optimization and safety margins; to set the starting dose; ...

journal_title：Drug discovery today

authors： Visser SA,Aurell M,Jones RD,Schuck VJ,Egnell AC,Peters SA,Brynne L,Yates JW,Jansson-Löfmark R,Tan B,Cooke M,Barry ST,Hughes A,Bredberg U

更新日期：2013-08-01 00:00:00

abstract：:In developed countries that protect core aspects of the fundamental human right to the highest attainable standard of health, how does that right intersect with intellectual property rights? Here, the human rights implication of providing access to all cancer drugs recommended by experts in a developed country is cons...

journal_title：Drug discovery today

authors： Khachigian LM

更新日期：2020-07-01 00:00:00

abstract：:Thermodynamic profiles of ligand binding, particularly enthalpically favored binding signatures, have been suggested as a criterion to support the decision-making process around which compounds to select for further optimization in drug development. The concept was enthusiastically taken up, but turned out to be too s...

journal_title：Drug discovery today

authors： Klebe G

更新日期：2019-04-01 00:00:00

abstract：:Amyotrophic lateral sclerosis (ALS) is one of the most complex motor neuron diseases. Even though scientific discoveries are accelerating with an unprecedented pace, to date more than 30 clinical trials have ended with failure and staggering frustration. There are too many compounds that increase life span in mice, bu...

journal_title：Drug discovery today

authors： Genç B,Özdinler PH

更新日期：2014-04-01 00:00:00

abstract：:Patients with severe asthma suffer persistent symptoms and/or frequent exacerbations despite high-intensity treatment. Their severe unrelenting symptoms have a huge impact on healthcare resources owing to frequent hospital admissions and requirement for intensive treatments. Consequently, there is an undeniable need f...

journal_title：Drug discovery today

authors： Polosa R,Casale T

更新日期：2012-06-01 00:00:00

abstract：:Lipidomics is a rapidly growing technology that can be used in biomedical research to study disease mechanisms, identify novel disease biomarkers and drug efficacy biomarkers, and reveal off-target effects. Lipidomics can also be used to elucidate the mechanism of action of different drug compounds or as readouts in M...

journal_title：Drug discovery today

authors： Vihervaara T,Suoniemi M,Laaksonen R

更新日期：2014-02-01 00:00:00

abstract：:Psoriasis is a chronic autoimmune skin disorder triggered by either genetic factors, environmental factors, life style, or a combination thereof. Clinical investigations have identified pathogenesis, such as T cell and cytokine-mediated, genetic disposition, antimicrobial peptides, lipocalin-2, galectin-3, vaspin, fra...

journal_title：Drug discovery today

authors： Rapalli VK,Waghule T,Gorantla S,Dubey SK,Saha RN,Singhvi G

更新日期：2020-12-01 00:00:00

abstract：:We have broken old surviving dogmas and concepts used in computational chemistry and created an efficient in silico ADME-T pharmacological properties modeling and prediction toolbox for any xenobiotic. With the help of an innovative and pragmatic approach combining various in silico techniques, like molecular modeling...

journal_title：Drug discovery today

authors： Jacob A,Pratuangdejkul J,Buffet S,Launay JM,Manivet P

更新日期：2009-04-01 00:00:00

abstract：:A quantitative analysis has cast doubt over the limited advantages provided by particles for nose-to-brain (NTB) drug delivery. Thus, it is imperative to identify the role of nanovehicles in NTB drug delivery. If nanocarriers are used merely as an option to improve various properties of the drugs or the formulations, ...

journal_title：Drug discovery today

authors： Feng Y,He H,Li F,Lu Y,Qi J,Wu W

更新日期：2018-05-01 00:00:00

abstract：:There is currently a marketed drug for nearly every nuclear receptor for which the natural ligand has been identified. However, because of the complexity of signal transduction by this class of ligand-regulated transcription factors, few of these drugs have been optimized for pharmaceutical effectiveness. Over the pas...

journal_title：Drug discovery today

authors： Pearce KH,Iannone MA,Simmons CA,Gray JG

更新日期：2004-09-01 00:00:00

abstract：:Telomerase is a ribonucleic reverse transcriptase enzyme that uses an integral RNA component as a template to add tandem telomeric DNA repeats, TTAGGG, at the 3' end of the chromosomes. 85-90% of human tumors and their derived cell lines predominantly express high levels of telomerase, therefore contributing to cancer...

journal_title：Drug discovery today

authors： Saraswati AP,Relitti N,Brindisi M,Gemma S,Zisterer D,Butini S,Campiani G

更新日期：2019-07-01 00:00:00

abstract：:Drug-delivery technologies for modified drug release have been in existence for decades, but their utilization has been largely limited to post-launch efforts improving therapeutic outcomes. Recently, they have gained renewed importance because the pharmaceutical industry is steadily shifting to a more integrated disc...

journal_title：Drug discovery today

authors： Yang W,Bhattachar SN,Patel PJ,Landis M,Patel D,Reid DL,Duvnjak Romic M

更新日期：2020-12-14 00:00:00

abstract：:In drug discovery and development (DDD), the efficacy, safety and cost of new chemical entities are the main concerns of the pharmaceutical industry. Continuously updated and stricter recommendations imposed by regulatory authorities result in greater challenges being faced by the industry. Reliable high-throughput te...

journal_title：Drug discovery today

authors： Khan SR,Baghdasarian A,Fahlman RP,Michail K,Siraki AG

更新日期：2014-05-01 00:00:00

abstract：:To date, the life sciences 'omics' revolution has not lived up to the expectation of boosting the drug discovery process. The major obstacle is dealing with the volume and diversity of data generated. An enhanced-science (e-science) approach based on remote collaboration, reuse of data and methods, and supported by a ...

journal_title：Drug discovery today

authors： Rauwerda H,Roos M,Hertzberger BO,Breit TM

更新日期：2006-03-01 00:00:00

abstract：:Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

journal_title：Drug discovery today

authors： Westwell A

更新日期：2001-02-01 00:00:00

abstract：:An overview of drugs approved by FDA in 2016 reveals dramatic disruptions in long-term trends. The number of new molecular entities (NMEs) dropped, reflecting the lowest rate of small-molecule approvals observed in almost five decades. In addition, the pace of industry consolidation slowed substantially. The impact of...

journal_title：Drug discovery today

authors： Griesenauer RH,Kinch MS

更新日期：2017-11-01 00:00:00

abstract：:Owing to their structural diversity, peptides are a unique source of innovative active ingredients. However, their development has been challenging because of their disadvantageous pharmacokinetic (PK) properties. Over the past decade, many attempts have been made to improve the oral bioavailability of peptide drugs. ...

journal_title：Drug discovery today

authors： Zizzari AT,Pliatsika D,Gall FM,Fischer T,Riedl R

更新日期：2021-01-23 00:00:00

abstract：:Oral delivery of peptides and proteins remains an attractive alternative to parenteral delivery and has challenged various attempts at delivery development. Incorporation of new tools into the delivery systems that can raise membrane permeability of macromolecules is essential to attain high oral bioavailability that ...

journal_title：Drug discovery today

authors： Morishita M,Peppas NA

更新日期：2006-10-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) has evolved from an untreatable condition to a disease for which several classes of drugs have now been approved, including various prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Because the pathogenesis of pulmonary hypertension is increasingly u...

journal_title：Drug discovery today

authors： Olsson KM,Hoeper MM

更新日期：2009-03-01 00:00:00

abstract：:Recent groundbreaking work in genetics has identified thousands of small-effect genetic variants throughout the genome that are associated with almost all major diseases. These genome-wide association studies (GWAS) are often proposed as a source of future medical breakthroughs. However, with several notable exception...

journal_title：Drug discovery today

authors： Folkersen L,Biswas S,Frederiksen KS,Keller P,Fox B,Fleckner J

更新日期：2015-10-01 00:00:00

abstract：:Intravitreal injection is one of the major administration routes for the treatment of posterior ocular diseases. Intravitreal therapeutics usually suffer from unsatisfactory efficacy owing to fast clearance from the vitreous humour and insufficient distribution into the retina. Engineered nanoparticles have been appli...

journal_title：Drug discovery today

authors： Huang X,Chau Y

更新日期：2019-08-01 00:00:00